Evidence map›Paper›PMID 42405329›Full record

ReviewFrontiers in cell and developmental biology2026

Tumor suppressor network dysregulation in neuroblastoma: molecular mechanisms and precision therapeutic opportunities.

Rohan Gupta, Sorabh Lakhanpal, Naveen Kumar, Rupak Nagraik, Karthikeyan Ravi, Shivanshu Sharma, Mosleh Mohammad Abomughaid, Smita Kumari, Niraj Kumar Jha

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rohan GuptaDepartment of Biotechnology and Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida, Uttar Pradesh, India.
Sorabh LakhanpalSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Naveen KumarDepartment of Physics, School of Basic and Applied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Rupak NagraikDepartment of Biotechnology, Graphic Era Deemed to Be University, Dehradun, Uttarakhand, India.
Karthikeyan RaviCentre for Herbal Pharmacology and Environmental Sustainability, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, India.
Shivanshu SharmaSchool of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India.
Mosleh Mohammad AbomughaidDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.
Smita KumariCollege of Pharmacy, The Ohio State University, Columbus, OH, United States.
Niraj Kumar JhaDepartment of Biotechnology and Bioengineering, School of Biosciences and Technology, Galgotias University, Greater Noida, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma is the most common extracranial solid malignancy in children and accounts for nearly 15% of paediatric cancer-related mortality, underscoring its substantial clinical burden. Although multimodal therapeutic strategies, including chemotherapy, surgical resection, radiotherapy, stem cell transplantation, and immunotherapy, have improved outcomes in low- and intermediate-risk disease, survival rates for high-risk neuroblastoma remain poor due to frequent relapse and treatment resistance. While oncogenic drivers, such as

Indexed as

epigenetic dysregulationneuroblastomaprecision oncologytargeted therapytumor suppressor genes

Identifiers

PMID42405329
PMCPMC13328478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.